TD Cowen lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps a Buy rating on the shares. The firm said some new offerings show promise and company’s role in Cigna’s new PBM model is potential positive, but material impact unlikely until at least 2027. That said, valuation overly discounts the weaker near-term outlook.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- GoodRx will not partner with TrumpRx, CBS News reports
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength
- GoodRx price target lowered to $4 from $4.25 at UBS